Terbinafine + Urea (Terbinafine + Urea)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antifungal means

Included in the formulation
АТХ:

D.01.A.E   Other antifungal agents for external use

Pharmacodynamics:

Combined antifungal agent for topical application.

Terbinafine

Inhibits squalene epoxidase in the cell membrane of fungi. The accumulation of squalene inside the cell leads to its destruction. It acts fungicidally against dermatophytes, yeast, yeast-like and dimorphic fungi.

Active with respect to Trichophyton, Microsporum canis and Epidermophyton floccosum, Candida albicans and Malassezia furfur (the causative agent of colored lichen).

Urea

Penetrates deep into the skin and nail plate, accumulates water molecules, due to which moisturizes the epidermis. Softens the horny layer of the cover epithelium. Increases dermatopenransitivity of terbinafine, creating its high concentration.

Pharmacokinetics:

Means for topical application, systemic action on the body does not have.

Indications:

It is used to treat and prevent fungal diseases of skin and nails caused by dermatophytes: Trichophyton, Microsporum canis and Epidermophyton floccosum; yeast-like fungi of the genus Candida. It is used for multi-colored lish caused by Pityrosporum orbiculare.

ICD-10

I.B35-B49.B35   Dermatophytosis

I.B35-B49.B35.2   Mycosis brushes

I.B35-B49.B35.3   Mycosis of the feet

I.B35-B49.B35.4   Mycosis of the trunk

I.B35-B49.B36.0   Multicolored lichen

I.B35-B49.B37.2   Candidiasis of skin and nails

Contraindications:

Age before 2 years, individual intolerance.

Carefully:

Pregnancy and lactation, hepatic and renal insufficiency, skin tumors, alcoholism, hypersensitivity.

Pregnancy and lactation:

Recommendations for FDA - Category C. It is used with caution, in cases where the expected effect exceeds the risk to the fetus and newborn.

Dosing and Administration:

Outerly, apply a thin layer on the skin and rub it 1-2 times a day.

Side effects:

Local reactions: itching and burning at the site of application.

Allergic reactions.

Overdose:

Cases of overdose are not described.

Treatment is symptomatic.

Interaction:

Clinically significant interactions are not described.

Special instructions:

If there is no clinical improvement, it is recommended to stop taking terbinafine for 2 weeks of regular use.

Instructions
Up